智通财经APP在《差异化创新管线收获在即，此时或是买入宜明昂科-B(01541)的最佳机会》中指出，康方生物的依沃西和K药头对头期中分析数据发表，为PD-1/VEGF双抗在肿瘤免疫治疗领域的前景带来了更大的想象空间。而就在8月初，宜明昂科的相似靶点分子IMM2510(VEGFxPD-L1 mAb-Trap)及 IMM27M(CTLA-4, ADCC+)与Instil Bio, Inc的全资子公司SynBioTx Inc.达成一项总额超20亿美元的BD合作。Yiming Enko-B (01541) opened nearly 15% higher. As of press release, it rose 14.98% to HK$5.68, with a turnover of HK$0.2033 million.
The Zhitong Finance App learned that Yiming Onko-B (01541) was nearly 15% higher. As of press release, it had risen 14.98% to HK$5.68, with a turnover of HK$0.2033 million.
According to the news, Yiming Angke recently announced that according to the licensing and cooperation agreement with SYNBIOTX, a wholly-owned subsidiary of Instil Bio (TIL.US), relating to IMM2510 and IMM27M, the company has collected recent payments of 5 million US dollars from SynbioTX, and has collected a total of 15 million US dollars in payments. The company expects to collect no more than $35 million of remaining potential payments in the future. Notably, Instil Bio (TIL.US) has accumulated a cumulative increase of nearly 5 times in the past five trading days.
The Zhitong Finance App pointed out in “The Harvest of the Differentiated Innovation Pipeline Is Imminent, Now May Be the Best Opportunity to Buy Yiming Angko-B (01541)” that Kangfang Biotech's Ivorian and K Pharmacol published early analysis data, bringing more room for imagination to the future of PD-1/VEGF dual antibodies in the field of tumor immunotherapy. At the beginning of August, IMM2510 (VEGFXPD-L1 mAB-Trap) and IMM27M (CTLA-4, ADCC+), and SynbioTX Inc., a wholly-owned subsidiary of Instil Bio, Inc., reached a BD cooperation totaling more than 2 billion US dollars.